Latest Concord Drugs stock price

Concord Drugs P/E Ratio

CONCORD • P/E ratio trend, valuation band, and sector comparison — all formatted to support journal-based trading review.
Current P/E Ratio
244.29
High Valuation
Very High - High growth expectations or significantly overvalued

Current Valuation Metrics

P/E Ratio 244.29
Current Price ₹83.06
EPS (TTM) ₹0.34
Exchange BSE

Valuation Signal

Signal Overvalued
Historical Avg 33.56
Historical Range 33.56 - 33.56
Percentile 100.0%

Sector Context

Sector Average 53.4
Sector Median 31.12
Sector Rank #11 of 132
Sector Percentile 8.3%

Earnings Breakdown (TTM)

TTM EPS ₹0.39
Sept 2025 ₹0.19
Mar 2025 ₹0.04

Key P/E Ratio Insights for Concord Drugs

  • Stock appears overvalued with PE of 244.29, suggesting caution for new investments
  • Current PE is 627.9% above historical average
  • Trading at premium to sector average PE of 53.4

View the CONCORD equity price for detailed stock performance.

P/E Ratio Historical Trend for Concord Drugs

Historical P/E ratio trend based on annual earnings data. Lower P/E ratios may indicate undervaluation, while higher ratios suggest growth expectations.

Historical P/E Ratio Data

Year P/E Ratio EPS (₹) Year-end Price (₹) Exchange Valuation
2022 33.56 0.97 ₹32.55 BSE High

Sector P/E Ratio Comparison

Comparing Concord Drugs with other companies in Healthcare sector
Sector Average
53.4
Sector Median
31.12
Lowest P/E
1.5
Highest P/E
628.04
Companies
132
Company Symbol P/E Ratio Market Cap (₹ Cr) Valuation
Welcure Drugs & Pharmace… WELCURE 1.5 ₹51 Low
Ind Swift Laboratories INDSWFTLAB 3.18 ₹733 Low
Murae Organisor MURAE 3.86 ₹55 Low
Fermenta Biotech FERMENTA 9.01 ₹1,010 Low
Zenith Drugs ZENITHDRUG 9.06 ₹84 Low
Galaxy Medicare GML 9.5 ₹32 Low
Balaxi Pharmaceuticals BALAXI 10.06 ₹139 Low
Natco Pharma NATCOPHARM 10.8 ₹17,006 Low
Vasundhara Rasayans VRL 11.3 ₹51 Low
Mohini Health & Hygiene MHHL 11.84 ₹69 Low